{
  "drug": "empagliflozin",
  "corpus_version": "v20260131-01",
  "generated_at": "2026-01-31T08:27:20.026Z",
  "source": "FDA FAERS via OpenFDA",
  "stats": {
    "total_reports": 500,
    "seriousness": {
      "serious": 389,
      "non_serious": 111,
      "unknown": 0
    },
    "age_distribution": {
      "0-17": 2,
      "18-40": 25,
      "41-64": 225,
      "65-84": 177,
      "85+": 6,
      "Unknown": 65
    },
    "sex_distribution": {
      "Male": 303,
      "Female": 166,
      "Unknown": 31
    },
    "outcome_distribution": {
      "Recovered/Resolved": 470,
      "Recovering/Resolving": 102,
      "Not Recovered/Not Resolved": 225,
      "Recovered with Sequelae": 12,
      "Fatal": 44,
      "Unknown": 465
    },
    "country_distribution": {
      "US": 189,
      "JP": 96,
      "GB": 72,
      "DE": 26,
      "ES": 11,
      "CA": 10,
      "AU": 10,
      "CZ": 9,
      "SK": 8,
      "IT": 7,
      "Other": 62
    },
    "reports_by_year": {
      "2015": 21,
      "2016": 95,
      "2017": 200,
      "2018": 184
    }
  },
  "disclaimer": "Based on reported adverse events in FDA FAERS. This visualization does not imply causality or risk.",
  "stats_hash": "58e1f06d8edbccbde333b57c0ce03e8ae072574e794dbfa110ae2bdb5f0058a7"
}